As a new type of foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system and can supply L-arginine hydrochloride from multiple well-known original manufacturers. With over a decade of market experience and cooperative technological transformation with manufacturers, HiSiaddi possesses extensive expertise in product compliance issues. Below is a compliance resolution case for L-arginine hydrochloride handled by HiSiaddi.
Contact HiSiaddi customer service for more inquiries regarding L-arginine hydrochloride product compliance.
Purchaser: NexMed Pharma Inc., California, USA – a mid-sized domestic high-end prescription pharmaceutical enterprise in the US. Core products include postoperative parenteral nutrition injection solutions, kidney disease-specific medical nutrition formula powders and clinical prescription dietary supplements, distributed through US nationwide hospital chains and specialized nephrology pharmacies. Raw material access strictly complies with US FDA 21CFR172.320, USP-NF monograph standards, cGMP specifications, dual Kosher and Halal finished product certifications and California CDFA imported raw material regulations.
The enterprise previously sourced injectable-grade L-arginine hydrochloride (CAS: 1119-34-2) exclusively from Ajinomoto (Japan). In 2025, it launched a Chinese supply chain optimization initiative and signed an annual procurement contract of 120 tons with a major domestic amino acid manufacturer. Prior to shipment of the initial 62-ton batch from Shanghai Port to Los Angeles, third-party customs pre-inspection and US FDA port pre-screening flagged five major compliance defects, locking the goods in the warehouse and preventing customs clearance. Unrectified shipment would result in direct cargo detention and return upon arrival at US ports. The domestic production manufacturer only held domestic food production licenses and national standard testing systems, lacking experience with North American drug administration filings and unable to independently rectify full sets of overseas compliance documentation. The client faced production line shutdowns, compensation for downstream hospital order breaches and massive port storage detention fees, thus fully entrusting HiSiaddi with one-stop full-chain compliance rectification.
Raw material grade: Injectable pharmaceutical grade (distinct from standard food/feed grade), formulated for human intravenous injection with compliance thresholds far exceeding low-grade civilian raw materials.
US regulations mandate overseas manufacturers of pharmaceutical amino acid raw materials to complete FDA FURLS factory registration, obtain an FEI enterprise code and designate a US-based compliance agent. APIs must be supported by Type II DMF technical dossiers referenceable by the client’s ANDA drug application numbers. The domestic manufacturer only completed domestic SC food production filings and ISO9001 certification without FDA factory registration or English DMF dossiers covering impurity profiles, process validation and stability data. The FDA pre-screening system flagged a lack of raw material filing records, prohibiting entry customs clearance.
The manufacturer’s dual certifications solely applied to corn starch fermentation feedstock, without full-process finished product factory audits for final L-arginine hydrochloride. The client’s prescription formulas serve Jewish and Muslim nephrology patients; US nationwide pharmacy shelf placement mandates finished product certificates verifiable on official Jewish headquarters and North American Halal Association websites. Non-compliant certificates block the client’s terminal product US pharmaceutical shelf filing.
Original manufacturer test certificates complied with national standard GB1886.235, with loose internal control limits for heavy metals, endotoxins, organic solvent residues, specific optical rotation and residue on ignition. USP mandates injectable-grade endotoxin ≤0.1 EU/mg and heavy metals ≤1 ppm; the factory’s tested batch endotoxin measured 0.35 EU/mg, failing pre-screening by US SGS and disqualifying the material for injection production.
1. Outer carton labels printed exclusively in Chinese, missing CAS number, sensitization hazard warnings, country of origin, FDA registration number and storage precautions, violating US raw material import labeling legislation.
2. Only Chinese-language MSDS available, lacking GHS hazard classifications (H315/H319 skin and eye irritation) and transportation/storage protection clauses unrecognized by US port warehouses and entry inspection authorities, preventing container pickup and loading.
The factory self-classified the goods under HS code 2309 for food additives, while injectable pharmaceutical-grade L-arginine hydrochloride legally falls under fine chemical API tariff code 29252900. Misclassification would trigger a 13%+ increase in US import tariffs plus targeted FDA full-container unpacking audits, with high probability of cargo detention and inspection.
1. HiSiaddi coordinated the factory’s quality, production and R&D departments on-site to collect Class 100,000 clean workshop floor plans, full-process fermentation and refining SOPs, three commercial batch process validation datasets and raw material traceability ledgers. A US licensed compliance agency was entrusted to process FDA FURLS factory registration, obtain FEI codes and sign a licensed US agent to receive and respond to official FDA correspondence.
2. Compiled English DMF dossiers aligned with FDA eCTD specifications, supplementing impurity traceability, 6-month accelerated stability data and ICH M7 genotoxic impurity assessment materials. Pre-submission of DMF obtained official FDA acknowledgment numbers enabling cross-reference via the client’s ANDA drug application numbers, completing full filing documentation within 19 working days.
HiSiaddi partnered with domestic certification bodies holding North American authorized qualifications to audit full production workflows from strain cultivation, fermentation feeding and membrane separation refining to finished product packaging. Non-compliant auxiliary materials were removed from production processes, followed by on-site factory audits to reissue exclusive dual certifications for finished L-arginine hydrochloride. Certificate numbers were uploaded to North American official databases for online authenticity verification by US drug administration bodies and chain pharmacies, satisfying mandatory US prescription formula filing requirements.
1. Coordinated factory optimization of refining processes with additional three-stage ultrafiltration for endotoxin removal; batches failing endotoxin limits were returned for secondary refining. Post-rectification, all batch endotoxin levels stabilized ≤0.08 EU/mg and heavy metals ≤0.8 ppm, fully falling within USP-NF control ranges.
2. Arranged full testing by both CNAS-accredited domestic laboratories and US SGS, issuing bilingual Chinese-English COA test reports itemized against USP pharmacopoeia standards with CAS numbers, internal control specifications and batch traceability codes to meet US pharmaceutical laboratory incoming material audit requirements.
1. Redesigned bilingual outer carton labels in compliance with US OSHA and California raw material labeling regulations, supplementing CAS 1119-34-2, country of origin, FEI registration number, sensitization hazard warnings and storage-transport conditions.
2. Compiled full English compliance MSDS aligned with product physicochemical parameters and GHS hazard warnings (H315/H319), covering all compliance requirements for ocean shipping, warehousing and production feeding to pass port and US entry inspection documentation reviews.
HiSiaddi assisted customs brokers in revising the tariff code to API classification 29252900, compiling classification explanations, product grade certificates and USP test reports for customs pre-review, correcting declaration elements to avoid tariff surcharges and audit risks arising from misclassification.
1. Client Side: The rectified 62 tons of injectable-grade L-arginine hydrochloride smoothly shipped from Shanghai and cleared customs without incident at Los Angeles Port, enabling on-schedule raw material production and timely US pharmacy launch of the client’s three kidney disease injection formulations. Comprehensive raw material procurement costs fell 29% versus prior Japanese imports, with a subsequent 120-ton annual long-term supply agreement signed alongside additional customized procurement intentions for arginine derivatives.
2. Production Manufacturer: Leveraging compliance rectification experience for this benchmark US high-end pharmaceutical client, the factory improved its full suite of FDA, USP and dual certification support systems, securing subsequent pharmaceutical-grade amino acid orders from pharmaceutical manufacturers in Germany and Australia with a minimum 25% price premium for high-end grades.
3. HiSiaddi Foreign Trade: Established standardized North American compliance service solutions for pharmaceutical-grade amino acids, forming a full-chain service covering overseas client regulatory review, factory qualification supplementation, product indicator alignment with pharmacopoeia standards, label documentation rectification and customs clearance compliance. The company continues to deliver end-to-end compliance support services for multiple amino acid API export projects targeting North American and European high-end raw material markets.
Most domestic amino acid manufacturers focus on standard domestic spot goods production, complying solely with national standards and domestic food compliance while lacking familiarity with European and American pharmaceutical regulatory frameworks and overseas certification support capabilities. Mid-to-high-end European and American pharmaceutical clients utilize raw materials for prescription drug production with stringent compliance systems; a single missing qualification triggers full-container return losses. Drawing on overseas compliance resources and industry regulatory expertise, HiSiaddi resolved five core compliance pain points across full dimensions including qualification registration, raw material quality control, document preparation and customs classification, breaking compliance barriers preventing domestic API access to high-end European and American pharmaceutical manufacturers.
Contact HiSiaddi customer service for more inquiries regarding L-arginine hydrochloride product compliance.
+86-13120989737 
info@hisiaddi.com 
English
